Vis enkel innførsel

dc.contributor.authorHøydahl, Martin Petter
dc.contributor.authorBusund, Rolf
dc.contributor.authorRösner, Assami
dc.contributor.authorKjønås, Didrik
dc.date.accessioned2024-02-05T13:49:36Z
dc.date.available2024-02-05T13:49:36Z
dc.date.issued2024-01-15
dc.description.abstractBackground: Treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI) was introduced in 2002. Since then, TAVI has become the primary treatment approach worldwide for advanced-age patients and younger patients with severe comorbidities. We aimed to evaluate the changes in patient demographics, complications, and mortality rates within 13 years.<p> <p>Methods: This retrospective observational study included 867 patients who underwent TAVI at the University Hospital of North Norway in Tromsø from 2008 to 2021. The 13-year period was divided into period 1 (2008–2012), period 2 (2013–2017), and period 3 (2018–2021). The primary objective was to evaluate the changes in periprocedural (30 days), early (30–365 days), and late mortality rates (>365 days) between the periods. The secondary objective was to evaluate late mortality rates by sex and age groups: <70 years, 70–79 years, 80–89 years, and ≥90 years.<p> <p>Results: The periprocedural mortality rates for periods 1, 2, and 3 were 10.3%, 2.9%, and 1.2%, respectively (P < 0.001). The early mortality rates were 5.6%, 5.8%, and 6.5%, respectively. No significant differences were observed in late mortality by sex or age group (<70, 70–79, and 80–89 years) with a median survival of 5.3–5.6 years. The median survival in patients aged ≥90 years was 4.0 years (P = 0.018).<p> <p>Conclusion: Our findings indicate that most patients are octogenarians, and the burden of their comorbidities should be highly considered compared to their age when evaluating the procedural outcomes. As the incidence of most complications related to TAVI has decreased, the rates of permanent pacemaker implantation remain high. Important advancements in diagnostics, valve technology, and procedural techniques have improved the periprocedural mortality rates; however, early mortality remains unchanged and poses a clinical challenge that needs to be addressed in the future.en_US
dc.identifier.citationHøydahl, M.P., Busund, R., Rösner, A. & Kjønås, D. (2024). Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study. <i>Frontiers in Cardiovascular Medicine, 11</i>.en_US
dc.identifier.cristinIDFRIDAID 2227133
dc.identifier.doi10.3389/fcvm.2024.1298346
dc.identifier.issn2297-055X
dc.identifier.urihttps://hdl.handle.net/10037/32847
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.relation.journalFrontiers in Cardiovascular Medicine
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleTranscatheter aortic valve implantation (from inception to standard treatment): a single-center observational studyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)